VERNON, BC, Jan. 13, 2022 /CNW/ – Doseology Sciences Inc. (CSE: MOOD) (“Doseology” or the “Company”) announces the appointment of Maryam Marissen as Chief Executive Officer and Director, effective immediately. Outgoing interim CEO and co-founder Daniel Vice will remain involved with the Company as an independent director. Doseology is a British Columbia-based, diversified life sciences company developing mushroom-based health and wellness solutions.
Ms. Marissen is an accomplished business leader, entrepreneur, and marketing strategist. With over two decades of relevant leadership experience, she brings a valuable combination of consumer product marketing, healthcare, and government relations experience to her new position. Ms. Marissen helped establish one of the first online personal care and wellness e-commerce stores in North America, and grew sales to several million dollars annually. She recently served as Managing Director of a national government relations and public affairs agency, overseeing advocacy campaigns on matters such as healthcare, education, and public policy.
As co-founder of a Vancouver biotech startup, Marissen was involved in psychedelic research for therapeutic applications, consulting with academic, industry, and regulatory stakeholders to develop clinical pathways to patient care. Since last fall, she has been advising Doseology on product research and commercialization strategy while preparing for the leadership role.
Ms. Marissen commented, “It’s a personal calling and an honour to lead Doseology during this next stage. Public advocacy for healthcare has long been my passion, so I’m excited to continue addressing mental health challenges by getting new solutions to the people who need them most, in a safe and medically-supervised way.”
Regarding the changes made to Health Canada’s Special Access Program (SAP) on January 5th, Ms. Marissen added, “I commend Health Canada for their recent amendment of the Special Access Program, which makes psychedelic-assisted therapies including those with psilocybin available to more Canadians in need. As the efficacy of such treatments is further proven by research I believe that Canada’s progressive approach may become a model for the world.”
Board Chair Ralph Olson added, “We recognize the tremendous achievements from outgoing CEO Daniel Vice, who will remain actively involved as an independent director”. On the role transition, Mr. Vice commented, “All of our work so far has led us to this proud moment. Maryam has the experience and vision we believe is required for the upcoming challenges of growth, further research, and commercialization. I’m excited to see Doseology enter this new phase and help move the entire industry forward.”
Under Ms. Marissen’s leadership, Doseology will focus on cultivation of functional mushrooms, and establishing clinical services to create profitable revenue streams. The company’s application for a Health Canada Dealer’s License was filed in November, and once approved, will allow for psilocybin-related research and cultivation. In preparation for the Dealer’s License, R&D along with channel partnerships are strategic goals.
On Behalf of the Board of Directors,
About Doseology Sciences Inc.
Doseology Sciences Inc. (CSE: MOOD) is a British Columbia-based diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.
Forward Looking Statements
This corporate update contains statements which constitute “forward–looking information” within the meaning of applicable securities laws. Forward–looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward–looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward–looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward–looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward–looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward–looking information except as otherwise required by applicable law.
No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
/NOT FOR DISTRIBUTION IN THE UNITED STATES OR DISSEMINATION IN THE UNITED STATES/
SOURCE Doseology Sciences Inc.
The post Doseology Appoints Maryam Marissen as CEO to Prepare for Next Growth Stage appeared first on CannabisFN.psilocybin mushroom psychedelic psychedelic research cse doseology regulation laws health canada research public policy